| Eligibility |
Inclusion Criteria:
1. Male or female patients at the age of 18 to below 75 years with the life expectancy of
at least three months.
2. Prior confirmed diagnosis of multiple myeloma and measurable disease in blood or urine
with at least one of the following: Serum M-protein = 5g/l, Urine M-protein = 200
mg/24 hours, In subjects without detectable serum or urine M-component, serum free
light chain (S-FLC) > 100 ml/l (involved light chain) and an abnormal serum
kappa/lambda ratio
3. Relapse or progression after 1 to 3 prior treatment lines, which have included
proteasome inhibitors (bortezomib, carfilzomib and/or ixazomib) and/or lenalidomide.
Refractoriness to bortezomib, ixazomib and/or lenalidomide is allowed in the preceding
cycle. Patients with previous autologous transplantation can be included.
4. Need of treatment of relapse or progression: IMWG criteria for relapse/progression
(paraprotein or hypercalcemia, renal insufficiency, anemia, bone disease (CRAB)
criteria or both). (Appendix 5)
5. Voluntary written consent must be given before performance of any study related
procedure not part of standard medical care, with the understanding that the patient
may withdraw consent at any time without prejudice to future medical care.
6. Females of childbearing potential (FCBP) must have a confirmed negative serum
pregnancy test within the 7 days prior to inclusion
7. Females of childbearing potential must use one effective method of contraception and
their partners condom during the study and for 120 days following the last study drug
treatment dose and male subjects who are sexually active with FCBP must agree to use
condom during the study and for 180 days following the last study drug treatment dose.
8. Eastern Cooperative Oncology Group (ECOG) performance status 0-2, or Karnofsky at
least 60.
9. Patients must meet the following adequate organ and bone marrow function within 21
days prior to inclusion:
- Absolute neutrophil count (ANC) 1,000/mm3 (= 1.0 x 109/L) and platelet count 75 x
109/L. Platelet transfusions to help patients meet eligibility criteria are not
allowed within 3 days before study enrollment. Granulocyte growth factors are
allowed to meet the inclusion criteria.
- Hemoglobin (Hb) = 80 g/l (use of erythropoietin and red blood cell transfusions
allowed by institutional guidelines, however the most recent red blood cells
(RBC) may not have given within 7 days prior to obtaining screening Hb
- Total bilirubin < 1.5 times the upper limit of the normal range (ULN).
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 times the
ULN.
- Calculated creatinine clearance = 40 mL/min (Cockcroft-Gault estimation of
creatinine clearance (CRcl): CRcl (mL/min) = (140 - age) x (weight [kg]) / 72 x
(serum creatinine [mg/dL]); for females, multiply by 0.85 (Cockcroft 1976, Luke
1990)
10. Patient must be willing and able to adhere to the study protocol visit schedule and
other protocol requirements.
11. Negative pregnancy test at inclusion if applicable
Exclusion criteria
Patients meeting any of the following exclusion criteria are not to be enrolled in the
study:
1. Female patients who are lactating or have a positive serum pregnancy test during the
screening period.
2. Major surgery within 28 days before enrollment.
3. Radiotherapy within 14 days before enrollment, but if the involved field is small, 7
days will be considered a sufficient interval before onset of the treatment.
4. Glucocorticoid therapy within the 14 days prior to inclusion that exceeds a cumulative
dose of 160 mg dexamethasone or 1000 mg prednisone.
5. Central nervous system involvement.
6. Infection requiring systemic antibiotic therapy or other serious infection within 14
days before study enrollment.
7. Active congestive heart failure (NYHA III-IV) (Appendix 3), symptomatic ischemia,
conduction abnormalities uncontrolled by conventional intervention, acute diffuse
infiltrative pulmonary disease, pericardial disease or myocardial infarction within 6
months prior to enrollment or left ventricular ejection fraction (LVEF) <40% within
one month before randomization.
8. Ongoing or active systemic infection, active hepatitis A, B or C virus infection, or
known human immunodeficiency virus (HIV) positivity.
9. Any other serious medical or psychiatric illness that could, in the investigator's
opinion, potentially interfere with the completion of treatment according to this
protocol.
10. Known allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
or to any of the study medications, their analogues, or excipients in the various
formulations of any agent.
11. Contraindication to dexamethasone or any of the required concomitant drugs or
supportive treatments, including hypersensitivity to antiviral drugs, or intolerance
to hydration due to pre-existing pulmonary or cardiac impairment.
12. Diagnosed or treated for another malignancy within 5 years before study enrollment or
previously diagnosed with another malignancy and have any evidence of residual
disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are
not excluded if they have undergone complete resection.
13. Patient has = Grade 3 peripheral neuropathy, or Grade 2 with pain on clinical
examination within the 14 days prior to inclusion.
14. Participation in another interventional study within the 28 days before this study
inclusion.
15. Patients refractory to carfilzomib or elotuzumab.
16. Primary plasma cell leukemia, systemic AL amyloidosis, Waldenström macroglobulinemia,
rare Immunoglobulin M (IgM) multiple myeloma, POEMS syndrome, myelodysplasia
17. Allogeneic or autologous stem cell transplantation planned
18. Participants receiving any other investigational agents or received within 60 days
19. Pleural effusions requiring thoracocentesis within the 14 days prior the inclusion.
20. Ascites requiring puncture within the 14 days prior to inclusion.
21. Previous allogeneic transplantation
22. Uncontrolled hypertension or uncontrolled diabetes despite medication
23. Known hepatic cirrhosis
24. Severe autoimmune disease
|
